|Ms. Kiran Mazumdar-Shaw||Founder, Chairman and Managing Director||20.41M||N/A||1953|
|Dr. Arun Suresh Chandavarkar B.Tech., M.S., Ph.D.(Chem Eng)||CEO, Joint MD & Exec. Director||33M||N/A||1961|
|Mr. Siddharth Mittal BCom, CA, CPA||Pres of Fin. & CFO||N/A||N/A||1978|
|Mr. Paul Vazhayil Thomas BS, MBA||VP & Head of Biosimilars - MAbs||N/A||N/A||1973|
|Mr. Suresh Subramanian||Sr. VP & Head of Branded Formulations Bus. - India||N/A||N/A||1963|
Biocon Limited, a biopharmaceutical company, develops, manufactures, and sells biopharmaceuticals for diabetes, cancer, and autoimmune conditions. The company operates through Small Molecule APIs & Generic Formulations, Biologics, Branded Formulations, and Research Services segments. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, narrow spectrum antibiotics, and antifungals; and branded formulations in the areas of metabolics, oncology, immunology, and auto immune indications. The company also provides biosimilars comprising recombinant human insulin, insulin glargine, insulin lispro, insulin aspart, and monoclonal antibodies and other biologics; Nimotuzumab, a biologic for head and neck cancer under the IOMAb EGFR name; and ALZUMAb, an itolizumab for the treatment of psoriasis. In addition, it offers branded formulations for various chronic therapeutic areas, such as metabolics, oncotherapeutics, immunotherapy, nephrology, virology, and specialty. The company's principal brands include INSUGEN, BASALOG, CANMAb, EVERTO, and Nufil. Further, it operates as a contract research organization that provides a suite of integrated drug discovery and development services for start-up companies, pharmaceuticals/biotech, agrochemical, chemical, and nutrition and animal health companies. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
Biocon Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.